Peroxisome proliferator activated-receptor ␣ (PPAR␣) is a ligand-activated transcription factor belonging to the nuclear receptor family. PPAR␣ is implicated in the regulation of lipid and glucose metabolism and in the control of inflammatory response. Recently, it has been demonstrated that a number of nuclear receptors are degraded by the ubiquitin-proteasome pathway. Since PPAR␣ exhibits a circadian expression rhythm and since PPAR␣ is rapidly regulated under certain pathophysiological conditions such as the acute phase inflammatory response, we hypothesized that PPAR␣ protein levels must be under tight control. Here, we studied the mechanisms controlling PPAR␣ protein levels and their consequences on the transcriptional control of PPAR␣ target genes. Using pulse-chase experiments, it is shown that PPAR␣ is a short-lived protein and that addition of its ligands stabilizes this nuclear receptor. By transient cotransfection experiments using expression vectors for PPAR␣ and hemagglutinin-tagged ubiquitin, it is demonstrated that PPAR␣ protein is ubiquitinated and that its ligands decrease the ubiquitination of this nuclear receptor, thus providing a mechanism for the ligand-dependent stabilization observed in pulse-chase experiments. In addition, treatment with MG132, a selective proteasome inhibitor, increases the level of ubiquitinated PPAR␣ and inhibits its degradation in transfected cells. Furthermore, MG132 treatment enhances the level of endogenous PPAR␣ in HepG2 cells. Finally, transient transfection and quantitative reverse transcription-PCR show that inhibition of PPAR␣ degradation increases its transcriptional activation and expression of target genes such as apoA-II and fatty acid transport protein (FATP). Taken together, these data demonstrate that PPAR␣ is degraded by the ubiquitin-proteasome system in a ligand-dependent manner. Regulation of its degradation provides a novel regulatory mechanism of transcriptional activity of this nuclear receptor.The peroxisome proliferator-activated receptors (PPARs) 1 are members of the nuclear receptor superfamily that act as ligand-dependent transcription factors. PPAR␣ is highly expressed in liver, skeletal and cardiac muscle, and proximal tubular epithelium of kidney. A significant expression of PPAR␣ has also been shown in endothelial cells, smooth muscle cells, and cells involved in the inflammatory process (1). The ligands of PPAR␣ are natural fatty acids and derivatives such as leukotriene B4 and 8-S-hydroxyeicosatetraenoic acid or oxidized phospholipids from oxidized low density lipoprotein. The fibrates hypolipidemic drugs are synthetic PPAR␣ ligands (1). PPAR␣ plays a role in intracellular fatty acid metabolism and in triglyceride metabolism by regulating genes involved in the transport and degradation of fatty acids in mitochondria and peroxisomes (2). PPAR␣ is also implicated in the metabolism of lipids and lipoproteins. As a result, PPAR␣ activation decreases the hepatic very low density lipoprotein secretion and plasma triglyceride levels (3). Fur...